Research

LIke ThisLIke ThisLIke This

Gregory  Priebe, MD

Gregory Priebe, MD
Department:
Medicine Research
Division
Infectious Diseases Research
Hospital Title:
Senior Associate in Critical Care Medicine; Senior Associate Physician in Medicine
Academic Title:
Associate Professor of Anesthesia, Harvard Medical School
Research Focus Area:
Pseudomonas aeruginosa infections
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Priebe’s laboratory studies immunity to the bacterial pathogens Pseudomonas aeruginosa and the Burkholderia cepacia complex, with the long-term goal of developing vaccines and immunotherapies. Techniques used in his group span multiple fields, including microbiology, molecular biology, genomics, cellular and molecular immunology, and animal models of infection.

A major focus of Dr. Priebe’s lab centers on evaluation of the mechanisms of protection of live-attenuated Pseudomonas vaccines. His group showed that Pseudomonas aroA deletion mutants, given intranasally, protect mice against acute Pseudomonas pneumonia and also against corneal infections. Antibodies alone can protect against corneal infections. However, for protection against pneumonia, both T cells and LPS-specific antibodies are needed. Rapid recruitment of neutrophils to the airways by the cytokine IL-17, which is secreted by helper CD4 T cells called Th17 cells, is critical for vaccine-induced protection in the non-neutropenic host, while CD4 T cells secreting GM-CSF are needed in the neutropenic host. Dr. Priebe’s lab also recently discovered Th17-stimulating Pseudomonas protein antigens that are effective intranasal vaccines in mice. Ongoing work is aimed at improving the potency and broadness of protection of these novel vaccines.

Another project in Dr. Priebe’s lab examines the roles of LPS and surface polysaccharides in the virulence of bacteria in the Burkholderia cepacia complex (BCC), including B. dolosa, which has caused an outbreak in the cystic fibrosis population at Boston Children's Hospital. Dr. Priebe’s group showed that a staphylococcal surface polysaccharide called poly N-acetyl-glucosamine is expressed by the BCC and is a target for antibody-mediated therapies, most notably for the nearly pan-resistant B. dolosa. In collaboration with the HMS Department of Systems Biology, Dr. Priebe’s team used whole-genome sequencing of B. dolosa isolates from the Boston Children’s Hospital outbreak to identifybacterial genes under strong positive selection, suggesting potential new antibiotic targets.

About Gregory Priebe

Dr. Priebe is a Senior Associate in the Division of Critical Care Medicine of the Department of Anesthesiology, Perioperative and Pain Medicine at Boston Children’s Hospital, where he attends in the Medical-Surgical Intensive Care Unit. He is also an Associate in the Division of Infectious Diseases of the Department of Medicine at Boston Children’s Hospital and an Assistant Professor of Anaesthesia (Pediatrics) at Harvard Medical School.

Dr. Priebe serves as the Associate Program Director for the Fellowship in Pediatric Critical Care Medicine, where he is the Director of Fellowship Research. In addition to his clinical and teaching responsibilities, Dr. Priebe chairs the hospital’s Nosocomial Infection Oversight Committee, which oversees healthcare-associated infection surveillance and infection prevention practices for the hospital’s 4 ICUs. He is also active in national working groups aimed at reducing and better defining healthcare-associated infections in children.

Dr. Priebe earned his medical degree from Harvard Medical School and then went on to complete residency and chief residency in Pediatrics at Boston Children’s Hospital followed by fellowships in Pediatric Infectious Diseases and Pediatric Critical Care Medicine, also at Boston Children’s Hospital. He is board certified in Pediatric Infectious Diseases and Pediatric Critical Care Medicine.

Key Publications

LiebermanTD, MichelJB, Aingaran M, Potter-Bynoe G, Roux D, Davis MR, Skurnik D, Leiby N, LiPuma JJ, Goldberg JB, McAdam AJ, Priebe GP, Kishony R. Parallel bacterial evolution within multiple patients ties novel genes to pathogenesis.  Nat Genetics 2011; 43(12):1275-80(PMCID3245322).

Skurnik D, Davis Jr. MR, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litràn T, Cassidy SB, Hermos CR, Martin TR, ThakkallapalliEL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, LiPuma JJ, Pier GB, Goldberg JB, Priebe GP. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205(11):1709-18. Epub 2012 Mar 23 (PMCID3415848).

Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.  Am J Respir Crit Care Med 2012;186(5):420-7. Epub 2012 Jun 21

Kamei A, Wu W, Traficante DC, Koh AY, Van RooijenN, Pier GB, Priebe GP.Collaboration between macrophages and vaccine-induced CD4 T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis 2012, Epub 2012 Nov 21.

Hong H, Morrow DF, Sandora TJ, Priebe GP.  Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity.  Am J Infect Control 2012, in press.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Albert BD, Zurakowski D, Bechard LJ, Priebe GP, Duggan CP, Heyland DK, Mehta NM. Enteral Nutrition and Acid-Suppressive Therapy in the PICU: Impact on the Risk of Ventilator-Associated Pneumonia. Pediatr Crit Care Med. 2016 Oct; 17(10):924-929.
  2. Cocoros NM, Kleinman K, Priebe GP, Gray JE, Logan LK, Larsen G, Sammons J, Toltzis P, Miroshnik I, Horan K, Burton M, Sims S, Harper M, Coffin S, Sandora TJ, Hocevar SN, Checchia PA, Klompas M, Lee GM. Ventilator-Associated Events in Neonates and Children--A New Paradigm. Crit Care Med. 2016 Jan; 44(1):14-22.
  3. Gauguet S, D'Ortona S, Ahnger-Pier K, Duan B, Surana NK, Lu R, Cywes-Bentley C, Gadjeva M, Shan Q, Priebe GP, Pier GB. Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia. Infect Immun. 2015 Oct; 83(10):4003-14.
  4. Flett KB, Ozonoff A, Graham DA, Sandora TJ, Priebe GP. Impact of Mandatory Public Reporting of Central Line-Associated Bloodstream Infections on Blood Culture and Antibiotic Utilization in Pediatric and Neonatal Intensive Care Units. Infect Control Hosp Epidemiol. 2015 Aug; 36(8):878-85.
  5. Klompas M, Branson R, Eichenwald EC, Greene LR, Howell MD, Lee G, Magill SS, Maragakis LL, Priebe GP, Speck K, Yokoe DS, Berenholtz SM. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Sep; 35 Suppl 2:S133-54.
  6. Priebe GP, Goldberg JB. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr; 13(4):507-19.
  7. Lieberman TD, Flett KB, Yelin I, Martin TR, McAdam AJ, Priebe GP, Kishony R. Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat Genet. 2014 Jan; 46(1):82-7.
  8. Djonovic S, Urbach JM, Drenkard E, Bush J, Feinbaum R, Ausubel JL, Traficante D, Risech M, Kocks C, Fischbach MA, Priebe GP, Ausubel FM. Trehalose biosynthesis promotes Pseudomonas aeruginosa pathogenicity in plants. PLoS Pathog. 2013 Mar; 9(3):e1003217.
  9. Hong H, Morrow DF, Sandora TJ, Priebe GP. Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity. Am J Infect Control. 2013 Aug; 41(8):e77-9.
  10. Kamei A, Wu W, Traficante DC, Koh AY, Van Rooijen N, Pier GB, Priebe GP. Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis. 2013 Jan 1; 207(1):39-49.
  11. Show all
  12. Tamang DL, Pirzai W, Priebe GP, Traficante DC, Pier GB, Falck JR, Morisseau C, Hammock BD, McCormick BA, Gronert K, Hurley BP. Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol. 2012 Nov 15; 189(10):4960-9.
  13. Zaidi TS, Zaidi T, Pier GB, Priebe GP. Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun. 2012 Oct; 80(10):3706-12.
  14. Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012 Sep 1; 186(5):420-7.
  15. Skurnik D, Davis MR, Benedetti D, Moravec KL, Cywes-Bentley C, Roux D, Traficante DC, Walsh RL, Maira-Litràn T, Cassidy SK, Hermos CR, Martin TR, Thakkallapalli EL, Vargas SO, McAdam AJ, Lieberman TD, Kishony R, Lipuma JJ, Pier GB, Goldberg JB, Priebe GP. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis. 2012 Jun; 205(11):1709-18.
  16. Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun. 2011 Mar; 79(3):1289-99.
  17. Benarafa C, Priebe GP, Remold-O'Donnell E. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med. 2007 Aug 6; 204(8):1901-9.
  18. Priebe GP. Sepsis in the immunocompromised child: the least studied with the most to gain. Pediatr Crit Care Med. 2005 May; 6(3 Suppl):S78-9.
  19. Pier GB, Boyer D, Preston M, Coleman FT, Llosa N, Mueschenborn-Koglin S, Theilacker C, Goldenberg H, Uchin J, Priebe GP, Grout M, Posner M, Cavacini L. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 1; 173(9):5671-8.
  20. Priebe GP, Pier GB. Vaccines for Pseudomonas aeruginosa. In: Ellis RW, Brodeur BR, editors. New bacterial vaccines. 2003; 261-283.
  21. Priebe GP, Arnold JH. High-frequency oscillatory ventilation in pediatric patients. Respir Care Clin N Am. 2001 Dec; 7(4):633-45.
  22. Heininger A, Ulrich M, Priebe G, Unertl K, Müller-Schauenburg A, Botzenhart K, Döring G. The effect of human serum DNAases on the ability to detect antibiotic-killed Escherichia coli in blood by PCR. J Med Microbiol. 2001 Mar; 50(3):243-8.
  23. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun. 2000 Jul; 68(7):3998-4004.
  24. Headrick LA, Richardson A, Priebe GP. Continuous improvement learning for residents. Pediatrics. 1998 Apr; 101(4 Pt 2):768-73; discussion 773-4.
  25. Priebe GP, Dean CR, Zaidi T, Meluleni GJ, Coleman FT, Coutinho YS, Noto MJ, Urban TA, Pier GB, Goldberg JB. The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun. 2004 Jul; 72(7):4224-32.
  26. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol. 2008 Oct 1; 181(7):4965-75.
  27. Koh AY, Priebe GP, Pier GB. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun. 2005 Apr; 73(4):2262-72.
  28. Gadjeva M, Paradis-Bleau C, Priebe GP, Fichorova R, Pier GB. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J Immunol. 2010 Jan 1; 184(1):296-302.
  29. Kamei A, Koh AY, Gadjeva M, Priebe GP, Lory S, Pier GB. Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model. J Infect Dis. 2010 Jan 1; 201(1):71-80.
  30. Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006 Feb; 74(2):975-83.
  31. Harris EW, D'Amico DJ, Bhisitkul R, Priebe GP, Petersen R. Bacterial subretinal abscess: a case report and review of the literature. Am J Ophthalmol. 2000 Jun; 129(6):778-85.
  32. Lieberman TD, Michel JB, Aingaran M, Potter-Bynoe G, Roux D, Davis MR, Skurnik D, Leiby N, LiPuma JJ, Goldberg JB, McAdam AJ, Priebe GP, Kishony R. Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet. 2011 Nov 13; 43(12):1275-80.
  33. Priebe GP, Brinig MM, Hatano K, Grout M, Coleman FT, Pier GB, Goldberg JB. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun. 2002 Mar; 70(3):1507-17.
  34. Koh AY, Priebe GP, Ray C, Van Rooijen N, Pier GB. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun. 2009 Dec; 77(12):5300-10.
  35. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun. 2003 Mar; 71(3):1453-61.
  36. Zaidi T, Zaidi T, Cywes-Bentley C, Lu R, Priebe GP, Pier GB. Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye. Infect Immun. 2014 Aug; 82(8):3483-91.
  37. Schlosser K, Smallwood C, Arnold J, Lee G, Priebe G, Walsh B, Santillana M. 1015: IDENTIFICATION OF PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS USING CONTINUOUS VENTILATOR DATA. Crit Care Med. 2016 Dec; 44(12 Suppl 1):330.
  38. Cronin J, Kinlay J, Lee G, Priebe G. 1214: PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS ARE RARELY ASSOCIATED WITH INFECTION. Crit Care Med. 2016 Dec; 44(12 Suppl 1):379.
LIke ThisLIke ThisLIke This
Close